Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2015-11-30
Target enrollment:
Participant gender:
Summary
The Data Monitoring Committee (DMC) for study 20060198 recommended that all subjects
discontinue treatment of study drug and continue to be followed for long term follow-up.
Amgen adopted the DMC recommendation.